两种抗抑郁药靶向抑郁症患者的共享与独特影像内表型
研究基于DTI数据用LDA模型识别MDD患者影像衍生因子,发现三个潜在因子维度并在独立样本验证。SNRI靶向患者独特表达因子1(与迟滞相关),SSRI靶向患者独特表达因子3(与认知损害相关),共享因子2与焦虑和睡眠障碍相关。因子负荷与HAMD子评分显著相关。
要点
- DTI连接指纹可沿三个潜在因子维度刻画MDD患者的异质性。
- SNRI靶向患者独特表达因子1,与迟滞相关,涉及DMN与认知控制网络耦合。
- SSRI靶向患者独特表达因子3,与认知损害相关,涉及认知控制与注意网络耦合。
核心结论
- MDD患者存在共享和独特的影像衍生因子,可能为个体化药物治疗决策提供信息。
研究设计与样本
- 研究纳入62例MDD患者和39例健康对照的DTI数据构建LDA贝叶斯模型,另用48例MDD患者验证稳健性。
- 采用典型相关分析探索各因子负荷与HAMD子评分的关联。
关键影像表现/征象
- 所有患者的影像衍生连接指纹可沿三个潜在因子维度分布,并在样本外数据集得到验证。
- 因子1由SNRI靶向患者独特表达,以默认模式网络与认知控制网络之间的耦合模式为特征。
- 因子3由SSRI靶向患者独特表达,以认知控制与注意网络内部耦合模式及威胁与奖赏网络间连接为特征。
- 共享因子2以默认模式网络内部耦合模式为特征。
诊断标准与关键数值
- 因子1与迟滞相关(r=0.4,p=0.037)。
- 因子3与认知损害相关(r=0.36,p=0.047)。
- 因子2与焦虑相关(r=0.54,p=0.005)并与睡眠障碍相关(r=0.37,p=0.032)。
临床应用与阅片要点
- DTI连接指纹的因子负荷可能辅助区分不同抗抑郁药靶向的MDD亚型。
- 阅片时可关注默认模式网络、认知控制网络、注意网络及威胁与奖赏网络间的耦合模式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Determining the clinical homogeneous and heterogeneous sets among depressive patients is the key to facilitate individual-level treatment decision.
METHODS: The diffusion tensor imaging (DTI) data of 62 patients with major depressive disorder (MDD) and 39 healthy controls were used to construct a Latent Dirichlet Allocation (LDA) Bayesian model. Another 48 MDD patients were used to verify the robustness. The LDA model was employed to identify both shared and unique imaging-derived factors of two typically antidepressant-targeted depressive patients, selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs). Furthermore, we applied canonical correlation analysis (CCA) between each factor loading and Hamilton depression rating scale (HAMD) sub-score, to explore the potential neurophysiological significance of each factor.
RESULTS: The results revealed the imaging-derived connectional fingerprint of all patients could be situated along three latent factor dimensions; such results were also verified by the out-of-sample dataset. Factor 1, uniquely expressed by SNRI-targeted patients, was associated with retardation (r = 0.4, p = 0.037) and characterized by coupling patterns between default mode network and cognitive control network. Factor 3, uniquely expressed by SSRI-targeted patients, was associated with cognitive impairment (r = 0.36, p = 0.047) and characterized by coupling patterns within cognitive control and attention network, and the connectivity between threat and reward network. Shared factor 2, characterized by coupling patterns within default mode network, was associated with anxiety (r = 0.54, p = 0.005) and sleep disturbance (r = 0.37, p = 0.032).
CONCLUSIONS: Our findings suggested that quantification of both homogeneity and heterogeneity within MDD may have the potential to inform rational design of pharmacological therapies.
KEY POINTS: • The shared and unique manifestations guiding pharmacotherapy of depressive patients are caused by the homogeneity and heterogeneity of underlying structural connections of the brain. • Both shared and unique factor loadings were found in different antidepressant-targeted patients. • Significant correlations between factor loading and HAMD sub-scores were found.
引用
- Xue, Shao, Wang, et al. Shared and unique imaging-derived endo-phenotypes of two typical antidepressant-applicative depressive patients. Eur Radiol. 2022. PMID: 35980436. doi:10.1007/s00330-022-09004-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。